Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Therapy
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Solid Tumor|Breast Cancer
Interventions: DRUG: Alvespimycin|DRUG: Trastuzumab|DRUG: Paclitaxel
Sponsor: Bristol-Myers Squibb